Investigation of Drug-drug Interaction of Ritonavir and Itraconazole on the Pharmacokinetics of SHR-A1811 in Subjects With HER2-expressing Advanced Breast Cancer
The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.
Advanced Breast Cancer
DRUG: SHR-A1811|DRUG: Ritonavir|DRUG: Itraconazole
The maximum concentration (Cmax) for SHR-A1811, Cycle 2 and Cycle 3. Each cycle is 21 days.|The maximum concentration (Cmax) for payload, Cycle 2 and Cycle 3. Each cycle is 21 days.|Area under the concentration curve from time 0 to 16 days (AUC0-16d) for SHR-A1811, Cycle 2 and Cycle 3. Each cycle is 21 days.|Area under the concentration curve from time 0 to 16 days (AUC0-16d) for payload, Cycle 2 and Cycle 3. Each cycle is 21 days.
Time to maximum plasma concentration (Tmax), Cycle 2 and Cycle 3. Each cycle is 21 days.|Terminal half-life (t1/2), Cycle 2 and Cycle 3. Each cycle is 21 days.|Area under the concentration curve from time 0 to infinity (AUCinf), Cycle 2 and Cycle 3. Each cycle is 21 days.|Clearance (CL), Cycle 2 and Cycle 3. Each cycle is 21 days.|Volume of distribution at steady state (Vss), Cycle 2 and Cycle 3. Each cycle is 21 days.|Incidence and severity of adverse events, From the beginning of screening period to approximately 3 months after the last dose.
The study is being conducted to evaluate the pharmacokinetics and safety of SHR-A1811 monotherapy and in combination with Ritonavir or Itraconazole in subjects with HER2-expressing advanced breast cancer.